Niagen Bioscience, Inc. (NAGE)

Name: Niagen Bioscience, Inc. (NAGE) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001386570 · Nasdaq · Medicinal Chemicals & Botanical Products

Sector Manufacturing
Incorporated DE
Fiscal year ends around Dec 31

For the year ended 2025-12-31, Niagen Bioscience, Inc. reported revenue of $129.42M. Revenue grew 29.9% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $129.08M.

Key ratios (year ended 2025-12-31)

64.3%

Gross margin

12.6%

Operating margin

13.4%

Net margin

22.7%

Return on year-end equity

29.9%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-08-04

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-30	2016-12-31
Revenue	$129.08M	$129.42M	$99.60M	$83.57M	$72.05M	$67.45M	$59.26M	$46.29M	$31.56M	$21.20M	n/a
Cost of Revenue	$46.16M	$46.23M	$38.01M	$32.79M	$29.25M	$25.96M	$23.98M	$20.52M	$15.50M	$10.72M	$11.27M
Gross Profit	$82.92M	$83.19M	$61.59M	$50.78M	$42.80M	$41.49M	$35.27M	$25.77M	$16.05M	$10.48M	$10.39M
R&D Expense	$6.50M	$6.33M	$6.02M	$4.96M	$4.83M	$3.83M	$3.42M	$4.42M	$5.48M	$4.01M	$2.52M
Operating Income	$10.60M	$16.28M	$7.73M	-$5.60M	-$18.63M	-$27.07M	-$19.85M	-$31.30M	-$33.17M	-$16.38M	-$2.91M
Depreciation & Amortization	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$607.0K	$510.0K	$332.0K
EBITDA	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-$32.56M	-$15.87M	-$2.57M
Net Income	$15.99M	$17.38M	$8.55M	-$4.94M	-$16.54M	-$27.13M	-$19.93M	-$32.15M	-$33.32M	-$11.38M	-$2.93M
EPS (Diluted)	n/a	$0.20	$0.11	-$0.07	-$0.24	-$0.40	-$0.33	n/a	n/a	n/a	n/a
Total Assets	$106.59M	$106.41M	$68.28M	$54.96M	$54.06M	$57.84M	$38.36M	$40.25M	$42.23M	$62.72M	$19.75M
Total Liabilities	$24.06M	$29.87M	$22.18M	$26.51M	$25.39M	$26.11M	$21.93M	$19.80M	$15.05M	$8.89M	$9.78M
Shareholders' Equity	$82.53M	$76.53M	$46.09M	$28.46M	$28.67M	$31.73M	$16.42M	$20.45M	$27.18M	$53.83M	$9.97M
Cash & Equivalents	n/a	n/a	$44.50M	$27.20M	$20.30M	$28.22M	$16.70M	$18.81M	n/a	n/a	n/a
Operating Cash Flow	$5.95M	$13.50M	$12.11M	$7.12M	-$15.10M	-$24.16M	-$10.60M	-$20.44M	-$20.91M	-$9.80M	-$2.94M
Capital Expenditures	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$743.0K	$1.32M	$1.17M	$1.50M
Free Cash Flow	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-$21.18M	-$22.23M	-$10.97M	-$4.44M
Share Repurchases	$5.37M	$251.0K	$0	n/a	n/a	n/a	n/a	n/a	$404.0K	$0	n/a
Shares Outstanding	78.91M	79.71M	77.33M	74.98M	74.57M	68.13M	61.88M	59.56M	55.1K	54.70M	37.54M
Weighted Average Diluted Shares	n/a	85.44M	78.12M	74.98M	69.73M	67.19M	61.07M	n/a	n/a	n/a	n/a
EPS (Basic)	n/a	$0.22	$0.11	-$0.07	-$0.24	-$0.40	-$0.33	n/a	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView